{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:19:46Z","timestamp":1767665986765,"version":"build-2065373602"},"reference-count":75,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/s1470-2045(12)70213-9","type":"journal-article","created":{"date-parts":[[2012,7,27]],"date-time":"2012-07-27T10:17:23Z","timestamp":1343384243000},"page":"e353-e361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":216,"title":["Markers for individualised therapy in endometrial carcinoma"],"prefix":"10.1016","volume":"13","author":[{"given":"Helga B","family":"Salvesen","sequence":"first","affiliation":[]},{"given":"Ingfrid S","family":"Haldorsen","sequence":"additional","affiliation":[]},{"given":"Jone","family":"Trovik","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(12)70213-9_bib1","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/S1470-2045(12)70213-9_bib2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(05)67063-8","article-title":"Endometrial cancer","volume":"366","author":"Amant","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(12)70213-9_bib3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJM199608293350907","article-title":"Endometrial carcinoma","volume":"335","author":"Rose","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(12)70213-9_bib4","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(12)70213-9_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(08)61767-5","article-title":"Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis","volume":"373","author":"Blake","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(12)70213-9_bib6","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/IGC.0b013e3182169239","article-title":"Adjuvant chemotherapy for endometrial cancer","volume":"21","author":"Tangjitgamol","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/S1470-2045(12)70213-9_bib7","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group","volume":"29","author":"Oza","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrclinonc.2010.216","article-title":"Emerging therapeutic targets in endometrial cancer","volume":"8","author":"Dedes","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib9","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1073\/pnas.0806514106","article-title":"Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation","volume":"106","author":"Salvesen","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1470-2045(12)70213-9_bib10","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jnci\/djp334","article-title":"A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment","volume":"101","author":"Taube","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S1470-2045(12)70213-9_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/S1470-2045(12)70213-9_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0090-8258(91)90086-K","article-title":"Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study","volume":"40","author":"Morrow","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib14","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.2004.08.159","article-title":"Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial","volume":"22","author":"Creutzberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib15","doi-asserted-by":"crossref","first-page":"194.e1","DOI":"10.1016\/j.ajog.2009.05.003","article-title":"Clinical factors affecting the diagnostic accuracy of assessing dilation and curettage vs frozen section specimens for histologic grade and depth of myometrial invasion in endometrial carcinoma","volume":"201","author":"Wang","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1046\/j.1365-2559.2003.01603.x","article-title":"Concordance of FIGO grade of endometrial adenocarcinomas in biopsy and hysterectomy specimens","volume":"42","author":"Mitchard","year":"2003","journal-title":"Histopathology"},{"key":"10.1016\/S1470-2045(12)70213-9_bib17","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2214\/AJR.06.1196","article-title":"MRI of malignant neoplasms of the uterine corpus and cervix","volume":"188","author":"Sala","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib18","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00330-009-1309-6","article-title":"Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging","volume":"19","author":"Kinkel","year":"2009","journal-title":"Eur Radiol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1586\/14737140.9.1.75","article-title":"PET and PET-CT imaging of gynecological malignancies: present role and future promise","volume":"9","author":"Basu","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/S1470-2045(12)70213-9_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.crad.2011.02.018","article-title":"Staging of endometrial carcinomas with MRI using traditional and novel MRI techniques","volume":"67","author":"Haldorsen","year":"2012","journal-title":"Clin Radiol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/uog.5295","article-title":"Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging","volume":"31","author":"Savelli","year":"2008","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib22","doi-asserted-by":"crossref","DOI":"10.1007\/s00330-012-2400-y","article-title":"Standard 1.5-T MRI of endometrial carcinomas: modest agreement between radiologists","author":"Haldorsen","year":"2012","journal-title":"Eur Radiol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ygyno.2010.10.023","article-title":"Three-dimensional ultrasound for assessing women with gynecological cancer: a systematic review","volume":"120","author":"Alc\u00e1zar","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/jmri.21412","article-title":"Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T","volume":"28","author":"Lin","year":"2008","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/S1470-2045(12)70213-9_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3233\/CBM-2009-0543","article-title":"Magnetic resonance lymphography: a novel technique for lymph node assessment in gynecologic malignancies","volume":"5","author":"Narayanan","year":"2009","journal-title":"Cancer Biomark"},{"key":"10.1016\/S1470-2045(12)70213-9_bib26","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/AOG.0b013e3181f39849","article-title":"Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer","volume":"116","author":"Lewin","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ygyno.2011.11.008","article-title":"Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification","volume":"125","author":"Werner","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"suppl","key":"10.1016\/S1470-2045(12)70213-9_bib28","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8","article-title":"Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study","volume":"60","author":"Creasman","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(12)70213-9_bib29","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/jnci\/djn397","article-title":"Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial","volume":"100","author":"Benedetti Panici","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S1470-2045(12)70213-9_bib30","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0140-6736(09)62002-X","article-title":"Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis","volume":"375","author":"Todo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(12)70213-9_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2217\/WHE.10.85","article-title":"The current status of lymphadenectomy in the management of endometrial cancer","volume":"7","author":"Creasman","year":"2011","journal-title":"Womens Health (Lond Engl)"},{"key":"10.1016\/S1470-2045(12)70213-9_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(08)61766-3","article-title":"Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study","volume":"373","author":"Kitchener","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(12)70213-9_bib33","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.2010.31.2124","article-title":"Influence of gynecologic oncologists on the survival of patients with endometrial cancer","volume":"29","author":"Chan","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib34","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ajog.2011.09.001","article-title":"Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer","volume":"205","author":"Sharma","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2012.01.050","article-title":"Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective","volume":"125","author":"Trovik","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib36","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/cncr.20040","article-title":"Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma","volume":"100","author":"Scholten","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(12)70213-9_bib37","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/00000478-200009000-00002","article-title":"A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis","volume":"24","author":"Lax","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/PAS.0b013e3182073ac0","article-title":"Significant variation in the assessment of cervical involvement in endometrial carcinoma: an interobserver variation study","volume":"35","author":"McCluggage","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib39","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.0.CO;2-U","article-title":"The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways","volume":"88","author":"Lax","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(12)70213-9_bib40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00428-003-0947-3","article-title":"Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification","volume":"444","author":"Lax","year":"2004","journal-title":"Virchows Arch"},{"key":"10.1016\/S1470-2045(12)70213-9_bib41","first-page":"3607","article-title":"Methylation of hMLH1 in a population-based series of endometrial carcinomas","volume":"6","author":"Salvesen","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(12)70213-9_bib42","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/1097-0142(20001015)89:8<1758::AID-CNCR16>3.0.CO;2-A","article-title":"Clinical significance of microsatellite instability in endometrial carcinoma","volume":"89","author":"Basil","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(12)70213-9_bib43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ajog.2008.04.043","article-title":"GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival","volume":"199","author":"Engelsen","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib44","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib45","doi-asserted-by":"crossref","first-page":"10669","DOI":"10.1158\/0008-5472.CAN-05-2620","article-title":"High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma","volume":"65","author":"Oda","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/S1470-2045(12)70213-9_bib46","first-page":"3005","article-title":"PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics","volume":"4","author":"Risinger","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(12)70213-9_bib47","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1158\/1078-0432.CCR-10-2412","article-title":"Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer","volume":"17","author":"Trovik","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(12)70213-9_bib48","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ajog.2006.02.045","article-title":"Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas","volume":"195","author":"Engelsen","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib49","first-page":"153","article-title":"Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis","volume":"6","author":"Salvesen","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(12)70213-9_bib50","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.2004.09.034","article-title":"Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer","volume":"22","author":"Stefansson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib51","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/01.MP.0000028573.34289.04","article-title":"Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype","volume":"15","author":"Schlosshauer","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib52","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/path.1310","article-title":"Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia","volume":"199","author":"Moreno-Bueno","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib53","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.1073\/pnas.0803379105","article-title":"Drug-sensitive FGFR2 mutations in endometrial carcinoma","volume":"105","author":"Dutt","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1470-2045(12)70213-9_bib54","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/annonc\/mdr368","article-title":"Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium","volume":"23","author":"Pradhan","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib55","first-page":"307","article-title":"HER-2\/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas","volume":"32","author":"Engelsen","year":"2008","journal-title":"Int J Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib56","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1067\/mob.2000.107328","article-title":"Pretreatment assessment of prognostic indicators in endometrial cancer","volume":"182","author":"Mariani","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib57","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ajog.2009.07.029","article-title":"Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting","volume":"201","author":"Wik","year":"2009","journal-title":"Am J Obstet Gynecol"},{"issue":"suppl","key":"10.1016\/S1470-2045(12)70213-9_bib58","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/cncr.2820710411","article-title":"Prognostic significance of hormone receptors in endometrial cancer","volume":"71","author":"Creasman","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(12)70213-9_bib59","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2007.03.042","article-title":"Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"106","author":"Singh","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib60","first-page":"5380","article-title":"Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationships to clinical and histopathological variables in endometrial cancer","volume":"46","author":"Kauppila","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/S1470-2045(12)70213-9_bib61","first-page":"CD007926","article-title":"Hormonal therapy in advanced or recurrent endometrial cancer","volume":"12","author":"Kokka","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/S1470-2045(12)70213-9_bib62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ygyno.2003.12.038","article-title":"A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma","volume":"93","author":"Oreskovic","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib63","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0002-9378(86)80018-7","article-title":"Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma","volume":"155","author":"Iversen","year":"1986","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib64","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/cncr.22465","article-title":"Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called \u2018low-risk\u2019 patients with well and moderately differentiated tumors","volume":"109","author":"Susini","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(12)70213-9_bib65","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2559.2004.01882.x","article-title":"Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type","volume":"44","author":"Stefansson","year":"2004","journal-title":"Histopathology"},{"key":"10.1016\/S1470-2045(12)70213-9_bib66","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.1999.17.5.1382","article-title":"Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study","volume":"17","author":"Salvesen","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib67","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2004.11.154","article-title":"Her-2\/neu overexpression and amplification in uterine papillary serous carcinoma","volume":"22","author":"Slomovitz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/gyno.2000.5751","article-title":"Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma","volume":"77","author":"Silverman","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib69","doi-asserted-by":"crossref","first-page":"7564","DOI":"10.1073\/pnas.0702507104","article-title":"Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity","volume":"104","author":"Saal","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1470-2045(12)70213-9_bib70","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/cncr.24282","article-title":"Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel","volume":"115","author":"Su","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(12)70213-9_bib71","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1158\/1078-0432.CCR-11-0715","article-title":"Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer","volume":"17","author":"Staff","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(12)70213-9_bib72","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer","volume":"18","author":"Brooks","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(12)70213-9_bib73","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2011.36.1196","article-title":"PI3K\/AKT\/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations","volume":"30","author":"Janku","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70213-9_bib74","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djm022","article-title":"Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect","volume":"99","author":"Jiang","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S1470-2045(12)70213-9_bib75","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2559.2011.04057.x","article-title":"Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas","volume":"60","author":"Halle","year":"2012","journal-title":"Histopathology"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204512702139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204512702139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:05:44Z","timestamp":1761458744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204512702139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":75,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S1470204512702139"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(12)70213-9","relation":{},"ISSN":["1470-2045"],"issn-type":[{"type":"print","value":"1470-2045"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Markers for individualised therapy in endometrial carcinoma","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(12)70213-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}